DeCure for Blepharospasm-oromandibular dystonia syndrome
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for blepharospasm-oromandibular dystonia syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBlepharospasm-oromandibular dystonia syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for blepharospasm-oromandibular dystonia syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fms related receptor tyrosine kinase 4 (FLT4) — FLT4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4BSJ · 2.5 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Thirty-nine patients with idiopathic blepharospasm-oromandibular dystonia syndrome were described in 1976; thirteen had blepharospasm alone, nine had oromandibular dystonia alone, and seventeen had both. No cause or hereditary basis was discovered. A 2004 study of 105 outpatients with idiopathic blepharospasm (54 cases) or blepharospasm with oromandibular dystonia (Meige’s syndrome, 51 cases) found that eleven developed Parkinson’s disease, compared with only two of 105 age- and sex-matched controls, suggesting these patients are more prone to develop parkinsonian symptoms.
A 2013 clinical guideline for diagnosing blepharospasm identified seven clinical items with satisfactory interobserver agreement: involuntary eyelid narrowing or closure due to orbicularis oculi spasms, bilateral spasms, synchronous spasms, stereotyped spasm pattern, sensory trick, inability to voluntarily suppress the spasms, and blink count at rest. No single item yielded satisfactory accuracy in discriminating patients from healthy subjects or those with other eyelid disturbances. The best combination, an algorithm starting with stereotyped, bilateral, and synchronous orbicularis oculi spasms inducing eyelid narrowing or closure, followed by recognition of sensory trick or increased blinking, gave 93% sensitivity and 90% specificity.
Botulinum neurotoxin is described as the first-line and mainstay treatment for blepharospasm in a 2018 review. Oral medications may be considered in tardive syndromes, parkinsonian conditions, or as adjuncts in patients with inadequate symptom control. Dopaminergic agents including levodopa and dopamine agonists, GABAergic agents such as benzodiazepines and baclofen, and anticholinergics such as trihexyphenidyl have been used with varying benefits. Dopamine-depleting agents including tetrabenazine, deutetrabenazine, and valbenazine have a role in secondary blepharospasm due to tardive syndromes. A 2016 article reviews botulinum toxin treatment for blepharospasm, orofacial and oromandibular dystonia, and hemifacial spasm, discussing technical aspects and reported outcomes. A 2021 systematic review of oromandibular dystonia notes it results from a variety of genetic and acquired etiologies and can occur as isolated or part of a combined dystonia syndrome, but provides no new trial data.
What is still missing are randomised controlled trials comparing oral medications against placebo or each other specifically in this syndrome, studies that stratify patients by whether blepharospasm is isolated or combined with oromandibular dystonia, and funding for long-term prospective work to clarify the natural history and the apparent link to Parkinson’s disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Neurology Neurosurgery & Psychiatry · 1976 · 256 citations · open access
Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia?
AbstractThirty-nine patients with the idiopathic blepharospasm-oromandibular dystonia syndrome are described. All presented in adult life, usually in the sixth decade; women were more commonly affected than men. Thirteen had blepharospasm alone, nine had oromandibular dystonia alone, and 17 had both. Torticollis or dystonic writer's camp preceded the syndrome in two patients. Eight other patients developed toritocollis, dystonic posturing of the arms, or involvement of respiratory muscles. No cause or hereditary basis for the illness were discovered. The evidence to indicate that this syndrome is due to an abnormality of extrapyramidal function, and that it is another example of adult-onset focal dystonia akin to spasmodic torticollis and dystonic writer's cramp, is discussed.
Development and validation of a clinical guideline for diagnosing blepharospasm
AbstractOBJECTIVE: To design and validate a clinical diagnostic guideline for aiding physicians in confirming or refuting suspected blepharospasm. METHODS: The guideline was developed and validated in a 3-step procedure: 1) identification of clinical items related to the phenomenology of blepharospasm, 2) assessment of the relevance of each item to the diagnosis of blepharospasm, and 3) evaluation of the reliability and diagnostic sensitivity/specificity of the selected clinical items. RESULTS: Of 19 clinical items initially identified, 7 were admitted by content validity analysis to further assessment. Both neurologists and ophthalmologists achieved satisfactory interobserver agreement for all 7 items, including "involuntary eyelid narrowing/closure due to orbicularis oculi spasms," "bilateral spasms," "synchronous spasms," "stereotyped spasm pattern," "sensory trick," "inability to voluntarily suppress the spasms," and "blink count at rest." Each selected item yielded unsatisfactory accuracy in discriminating patients with blepharospasm from healthy subjects and patients with other eyelid disturbances. Combining the selected items, however, improved diagnostic sensitivity/specificity. The best combination, yielding 93% sensitivity and 90% specificity, was an algorithm starting with the item "stereotyped, bilateral, and synchronous orbicularis oculi spasms inducing eyelid narrowing/closure" and followed by recognition of "sensory trick" or, alternatively, "increased blinking." CONCLUSION: This study provides an accurate and valid clinical guideline for diagnosing blepharospasm. Use of this guideline would make it easier for providers to recognize dystonia in clinical and research settings.
Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm
AbstractBlepharospasm is a focal dystonia characterized by involuntary, repetitive eye closure. Orofacial and oromandibular dystonia describe involuntary dystonic movements of orofacial and oromandibular musculature. Hemifacial spasm is characterized by repetitive synchronous contraction of facial nerve innervated muscles on one side of the face. In this article, the clinical presentation, epidemiology, and approaches to treatment are reviewed. Technical aspects of using botulinum toxin for treatment and reported outcomes are discussed.
Development of Parkinson's disease in patients with blepharospasm
AbstractThe liability to develop parkinsonian symptoms was evaluated in 105 outpatients with idiopathic blepharospasm (IBS; 54 cases) or IBS associated to oromandibular dystonia (Meige's syndrome; 51 cases) mean age 70.3 +/- 9.6 years, and compared with an age- and sex-matched population. Eleven patients developed Parkinson's disease in the blepharospasm group, whereas only 2 of 105 patients were affected in the control group. Our results suggest that patients with IBS either isolated or associated with oromandibular dystonia are more prone to develop parkinsonian symptoms.
Annals of Indian Academy of Neurology · 2021 · 28 citations · open access
Oromandibular Dystonia – A Systematic Review
AbstractOromandibular dystonia (OMD) is a clinical problem which is commonly encountered in the practice of movement disorders. OMD results from a variety of genetic and acquired etiologies and can occur as an isolated manifestation, or as part of an isolated generalized or a combined dystonia syndrome. There are only very few systematic reviews on this condition which often causes significant disability. We review here the etiology, clinical features, diagnostic approach and management of OMD.
Expert Review of Ophthalmology · 2018 · 2 citations
Medical treatment of blepharospasm
AbstractIntroduction: Blepharospasm is a focal dystonia manifested by repetitive spasms of eyelid muscles, resulting in involuntary eye closure, often accompanied by other facial and neck muscle sustained contractions (cranial–cervical dystonia). Abnormalities in multiple pathways involving the basal ganglia, and aberrant dopaminergic, GABAergic, serotonergic and cholinergic systems have been implicated in blepharospasm and considered as potential targets for pharmacological intervention.Areas covered: Literature was reviewed for relevant case reports, case series, review articles, and update reports on blepharospasm and treatment of blepharospasm including articles on botulinum toxin and other pharmacological interventions.Expert commentary: Botulinum neurotoxin (BoNT) is the first line and mainstay of treatment for blepharospasm. Oral medications for the treatment of blepharospasm may be considered in tardive syndromes, parkinsonian conditions, and as adjunct to BoNT in patients with inadequate symptom control. Dopaminergic agents including levodopa and dopamine agonists, GABAergic agents such as benzodiazepines and baclofen, and anticholinergics such as trihexyphenidyl have been used in patients with blepharospasm with varying benefits. Dopamine-depleting agents including tetrabenazine, deutetrabenazine, and valbenazine have a role in the treatment of secondary blepharospasm due to tardive syndromes.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
